MASCC Antiemetics Study Group
Co-chair: Richard J. Gralla, MD - USA
Co-chair: Alexander Molassiotis, RN,MSc, PhD - United Kingdom
Study Group Minutes
2010 Minutes (PDF) - Vancouver, Canada
Guidelines & Assessment Tools
Antiemetic Guidelines UPDATED January 2013
MAT - Now available on the iphone in the App Store
Brief Update on MASCC Antiemetic Subcommittee
The antiemetic subcommittee is one of the oldest of the MASCC committees. It was established to deal with the important issue of control of nausea and vomiting induced by chemotherapy and radiotherapy.
During the Congress held in Luxembourg in September 1995 the Subcommittee decided to organize a consensus conference on the use of antiemetics. To identify the most important topics on which consensus should be measured and developed, the Subcommittee elaborated a questionnaire and circulated it to experts. The results of this survey were published (Ballatori E, Roila F, De Angelis V, et al. Clinical and methodological issues in antiemetic therapy: a worldwide survey of experts' opinions. Support Care Cancer 1997; 5: 269-273) and eight major issues were identified that would constitute the basis for the conference. The Consensus Conference was held in Perugia, Italy, 28-29 April 1997 and the papers presented in the eight sessions, corresponding exactly to the issues highlighted by the questionnaire, were published in detail the MASCC Journal (Support Care Cancer 1998; 6: 167-265) and summarized in the ESMO Journal (Ann Oncol 1998; 9: 811-819).
In the following years the Subcommittee has worked in two directions. First, starting from the observation that different recommendations had been made about antiemetic prophylaxis by different published guidelines (ASCO, ESMO, MASCC, NCCN, ASHP, etc), a unified consensus conference was held in New York 19-20 April 2001. The final document of the conference was presented during the ASCO - MASCC Joint Session held in San Francisco May 14, 2001. Second, the members of the Subcommittee have always been most concerned about the evidence that the transferability to clinical practice of results of the antiemetic clinical trials was moderate. To address this problem the Subcommittee planned an international drug utilization study evaluating antiemetic prescriptions and effectiveness against delayed emesis induced by chemotherapy that despite an optimal prophylaxis remains one of the unsolved problems of antiemetic therapy.
A Guide to Oncology Symptom Management
Edited by C.G. Brown. 2010 - 20% MASCC Discount. From symptoms found in older adults to common symptoms such as chemotherapy-induced nausea and vomiting, cancer-related fatigue, and oral mucositis, this best-selling book offers a complete overview of common symptoms and problems that affect patients with cancer.
Books on Supportive Care >>VIEW ALL - MASCC Member Discounts
MASCC Endorsed Guideline Partnerships
Acute AINV Guideline
From the Pediatric Oncology Group of Ontario (POGO)
Guideline for the Prevention of Acute Nausea and Vomiting due to Antineoplastic Medication in Pediatric Cancer Patients
The purpose of this guideline is to provide health care providers with an approach to the prevention of acute antineoplastic-induced nausea and vomiting (AINV) in children who are receiving antineoplastic medication. The scope is limited to the prevention of AINV in the acute phase (within 24 hours of administration of an antineoplastic agent). >> MORE
MASCC Study Group Coordinator, Anne Young